Literature DB >> 8797067

Does a placebo-effect exist in clinical trials on multiple sclerosis? Review of the literature.

L La Mantia1, M Eoli, A Salmaggi, C Milanese.   

Abstract

To verify whether the outcome in placebo-treated MS patients actually corresponds to that expected on the basis of the natural history and pretrial evolution of the disease, we here review the results of clinical trials conducted according to a placebo-controlled, randomized design, regardless of the experimental therapy used. The frequency of relapse in remitting-relapsing patients decreases during follow-up, and disability in progressive cases increases more slowly than before enrollment. These data should be borne in mind when evaluating the impact of experimental drugs on the natural course of the disease.

Entities:  

Mesh:

Year:  1996        PMID: 8797067     DOI: 10.1007/bf02000844

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  26 in total

1.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

2.  Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.

Authors:  J H Noseworthy; M K Vandervoort; C J Wong; G C Ebers
Journal:  Neurology       Date:  1990-06       Impact factor: 9.910

3.  Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group.

Authors: 
Journal:  Ann Neurol       Date:  1990-06       Impact factor: 10.422

4.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.

Authors:  B G Weinshenker; B Bass; G P Rice; J Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1989-02       Impact factor: 13.501

5.  The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.

Authors: 
Journal:  Lancet       Date:  1991-02-23       Impact factor: 79.321

6.  A double blind study on azathioprine efficacy in multiple sclerosis: final report.

Authors:  C Milanese; L La Mantia; A Salmaggi; M Eoli
Journal:  J Neurol       Date:  1993-05       Impact factor: 4.849

7.  Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials.

Authors:  D E Goodkin; D Hertsgaard; R A Rudick
Journal:  Arch Neurol       Date:  1989-10

8.  Double blind study of intrathecal beta-interferon in multiple sclerosis: clinical and laboratory results.

Authors:  C Milanese; A Salmaggi; L La Mantia; A Campi; M Eoli; M Savoiardo; G Bianchi; A Nespolo
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-07       Impact factor: 10.154

9.  Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis.

Authors:  D L Camenga; K P Johnson; M Alter; C D Engelhardt; P S Fishman; J I Greenstein; A S Haley; R L Hirsch; J E Kleiner; V Y Kofie
Journal:  Arch Neurol       Date:  1986-12

10.  A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis.

Authors:  G W Ellison; L W Myers; M R Mickey; M C Graves; W W Tourtellotte; K Syndulko; M I Holevoet-Howson; C D Lerner; M V Frane; P Pettler-Jennings
Journal:  Neurology       Date:  1989-08       Impact factor: 9.910

View more
  1 in total

1.  Ravines and sugar pills: defending deceptive placebo use.

Authors:  Jonathan Pugh
Journal:  J Med Philos       Date:  2014-12-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.